Clinical significance of P‑class pumps in cancer (Review)
- Authors:
- Sophia C. Themistocleous
- Andreas Yiallouris
- Constantinos Tsioutis
- Apostolos Zaravinos
- Elizabeth O. Johnson
- Ioannis Patrikios
-
Affiliations: Department of Medicine, School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus, Department of Life Sciences, School of Sciences, European University Cyprus, 2404 Nicosia, Cyprus - Published online on: July 12, 2021 https://doi.org/10.3892/ol.2021.12919
- Article Number: 658
-
Copyright: © Themistocleous et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Lauger P: Dynamics of ion transport systems in membranes. Physiol Rev. 67:1296–1331. 1987. View Article : Google Scholar : PubMed/NCBI | |
Pedersen PL: Transport ATPases into the year 2008: A brief overview related to types, structures, functions and roles in health and disease. J Bioenerg Biomembr. 39:349–355. 2007. View Article : Google Scholar : PubMed/NCBI | |
Apell HJ: Structure-function relationship in P-type ATPases-a biophysical approach. Rev Physiol Biochem Pharmacol. 150:1–35. 2003. View Article : Google Scholar : PubMed/NCBI | |
Litan A and Langhans SA: Cancer as a channelopathy: Ion channels and pumps in tumor development and progression. Front Cell Neurosci. 9:862015. View Article : Google Scholar : PubMed/NCBI | |
Palmgren MG and Nissen P: P-type ATPases. Annu Rev Biophys. 40:243–266. 2011. View Article : Google Scholar : PubMed/NCBI | |
Palmgren MG and Axelsen KB: Evolution of P-type ATPases. Biochim Biophys Acta. 1365:37–45. 1998. View Article : Google Scholar : PubMed/NCBI | |
Kühlbrandt W: Biology, structure and mechanism of P-type ATPases. Nat Rev Mol Cell Biol. 5:282–295. 2004. View Article : Google Scholar | |
Clausen MV, Hilbers F and Poulsen H: The structure and function of the Na,K-ATPase isoforms in health and disease. Front Physiol. 8:3712017. View Article : Google Scholar : PubMed/NCBI | |
Toyoshima C, Nakasako M, Nomura H and Ogawa H: Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 A resolution. Nature. 405:647–655. 2000. View Article : Google Scholar : PubMed/NCBI | |
Gu M, Zhang Y, Zhou X, Ma H, Yao H and Ji F: Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines. Oncol Lett. 8:1739–1744. 2014. View Article : Google Scholar : PubMed/NCBI | |
Newman RA, Kondo Y, Yokoyama T, Dixon S, Cartwright C, Chan D, Johansen M and Yang P: Autophagic cell death of human pancreatic tumor cells mediated by Oleandrin, a lipid-soluble cardiac glycoside. Integr Cancer Ther. 6:354–364. 2007. View Article : Google Scholar : PubMed/NCBI | |
Ihenetu K, Qazzaz HM, Crespo F, Fernandez-Botran R and Valdes R Jr: Digoxin-Like immunoreactive factors induce apoptosis in human acute T-cell lymphoblastic leukemia. Clin Chem. 53:1315–1322. 2007. View Article : Google Scholar : PubMed/NCBI | |
Wong VK, Li T, Law BY, Ma ED, Yip NC, Michelangeli F, Law CK, Zhang MM, Lam KY, Chan PL and Liu L: Saikosaponin-d, a novel SERCA inhibitor, induces autophagic cell death in apoptosis-defective cells. Cell Death Dis. 4:e7202013. View Article : Google Scholar : PubMed/NCBI | |
Rajasekaran SA, Huynh TP, Wolle DG, Espineda CE, Inge LJ, Skay A, Lassman C, Nicholas SB, Harper JF, Reeves AE, et al: Na,K-ATPase subunits as markers for epithelial-mesenchymal transition in cancer and fibrosis. Mol Cancer Ther. 9:1515–1524. 2010. View Article : Google Scholar : PubMed/NCBI | |
Dang D and Rao R: Calcium-ATPases: Gene disorders and dysregulation in cancer. Biochim Biophys Acta. 1863:1344–1350. 2016. View Article : Google Scholar : PubMed/NCBI | |
Arimochi J, Ohashi-Kobayashi A and Maeda M: Interaction of Mat-8 (FXYD-3) with Na+/K+-ATPase in colorectal cancer cells. Biol Pharm Bull. 30:648–654. 2007. View Article : Google Scholar : PubMed/NCBI | |
De Milito A and Fais S: Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol. 1:779–786. 2005. View Article : Google Scholar : PubMed/NCBI | |
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yiallouris A, Stephanou A and Patrikios I: Anticancer properties of Na+/K+-ATPase: A mini review. Asian J Sci Technol. 7:2864–2868. 2015. | |
Chakraborti S and Dhalla NS: Regulation of membrane Na+-K+ ATPase. Springer International Publishing; Cham: 2016, View Article : Google Scholar | |
Dyla M, Kjærgaard M, Poulsen H and Nissen P: Structure and mechanism of P-Type ATPase ion pumps. Annu Rev Biochem. 89:583–603. 2020. View Article : Google Scholar : PubMed/NCBI | |
Li Z, Zhang Z, Xie JX, Li X, Tian J, Cai T, Cui H, Ding H, Shapiro JI and Xie Z: Na/K-ATPase mimetic pNaKtide peptide inhibits the growth of human cancer cells. J Biol Chem. 286:32394–32403. 2011. View Article : Google Scholar : PubMed/NCBI | |
Edwards IJ, Bruce G, Lawrenson C, Howe L, Clapcote SJ, Deuchars SA and Deuchars J: Na+/K+ ATPase α1 and α3 isoforms are differentially expressed in α- and ү-motoneurons. J Neurosci. 33:9913–9919. 2013. View Article : Google Scholar : PubMed/NCBI | |
Pirahanchi Y, Jessu R and Aeddula NR: Physiology, sodium potassium pump. StatPearls. StatPearls Publishing; Treasure Island, FL: 2021 | |
Lingrel JB and Kuntzweiler T: Na+,K(+)-ATPase. J Biol Chem. 269:19659–19662. 1994. View Article : Google Scholar : PubMed/NCBI | |
Kaplan JH: Biochemistry of Na,K-ATPase. Annu Rev Biochem. 71:511–535. 2002. View Article : Google Scholar : PubMed/NCBI | |
Pietrini G, Matteoli M, Banker G and Caplan MJ: Isoforms of the Na,K-ATPase are present in both axons and dendrites of hippocampal neurons in culture. Proc Natl Acad Sci USA. 89:8414–8418. 1992. View Article : Google Scholar : PubMed/NCBI | |
Nawata J, Ohno I, Isoyama S, Suzuki J, Miura S, Ikeda J and Shirato K: Differential expression of alpha 1, alpha 3 and alpha 5 integrin subunits in acute and chronic stages of myocardial infarction in rats. Cardiovasc Res. 43:371–381. 1999. View Article : Google Scholar : PubMed/NCBI | |
Underhill DA, Canfield VA, Dahl JP, Gros P and Levenson R: The Na,K-ATPase alpha4 gene (Atp1a4) encodes a ouabain-resistant alpha subunit and is tightly linked to the alpha2 gene (Atp1a2) on mouse chromosome 1. Biochemistry. 38:14746–14751. 1999. View Article : Google Scholar : PubMed/NCBI | |
Makita N, Bennett PB Jr and George AL Jr: Voltage-gated Na+ channel beta 1 subunit mRNA expressed in adult human skeletal muscle, heart, and brain is encoded by a single gene. J Biol Chem. 269:7571–7578. 1994. View Article : Google Scholar : PubMed/NCBI | |
Hilbers F, Kopec W, Isaksen TJ, Holm TH, Lykke-Hartmann K, Nissen P, Khandelia H and Poulsen H: Tuning of the Na,K-ATPase by the beta subunit. Sci Rep. 6:204422016. View Article : Google Scholar : PubMed/NCBI | |
Mobasheri A, Trujillo E, Arteaga MF and Martín-Vasallo P: Na(+), K(+)-ATPase subunit composition in a human chondrocyte cell line; evidence for the presence of α1, α3, β1, β2 and β3 isoforms. Int J Mol Sci. 13:5019–5034. 2012. View Article : Google Scholar : PubMed/NCBI | |
Sundaram SM, Safina D, Ehrkamp A, Faissner A, Heumann R and Dietzel ID: Differential expression patterns of sodium potassium ATPase alpha and beta subunit isoforms in mouse brain during postnatal development. Neurochem Int. 128:163–174. 2019. View Article : Google Scholar : PubMed/NCBI | |
Malik N, Canfield VA, Beckers MC, Gros P and Levenson R: Identification of the mammalian Na,K-ATPase 3 subunit. J Biol Chem. 271:22754–22758. 1996. View Article : Google Scholar : PubMed/NCBI | |
Pestov NB, Zhao H, Basrur V and Modyanov NN: Isolation and characterization of BetaM protein encoded by ATP1B4-a unique member of the Na,K-ATPase β-subunit gene family. Biochem Biophys Res Commun. 412:543–548. 2011. View Article : Google Scholar : PubMed/NCBI | |
Mijatovic T, Dufrasne F and Kiss R: Na+/K+-ATPase and cancer. Pharm Pat Anal. 1:91–106. 2012. View Article : Google Scholar : PubMed/NCBI | |
Hundal HS, Marette A, Ramlal T, Liu Z and Klip A: Expression of beta subunit isoforms of the Na+,K(+)-ATPase is muscle type-specific. FEBS Lett. 328:253–258. 1993. View Article : Google Scholar : PubMed/NCBI | |
Jia LG, Donnet C, Bogaev RC, Blatt RJ, McKinney CE, Day KH, Berr SS, Jones LR, Moorman JR, Sweadner KJ and Tucker AL: Hypertrophy, increased ejection fraction, and reduced Na-K-ATPase activity in phospholemman-deficient mice. Am J Physiol Heart Circ Physiol. 288:H1982–H1988. 2005. View Article : Google Scholar : PubMed/NCBI | |
Jones DH, Li TY, Arystarkhova E, Barr KJ, Wetzel RK, Peng J, Markham K, Sweadner KJ, Fong GH and Kidder GM: Na,K-ATPase from mice lacking the gamma subunit (FXYD2) exhibits altered Na+ affinity and decreased thermal stability. J Biol Chem. 280:19003–19011. 2005. View Article : Google Scholar : PubMed/NCBI | |
Morrison BW, Moorman JR, Kowdley GC, Kobayashi YM, Jones LR and Leder P: Mat-8, a novel phospholemman-like protein expressed in human breast tumors, induces a chloride conductance in xenopus oocytes. J Biol Chem. 270:2176–2182. 1995. View Article : Google Scholar : PubMed/NCBI | |
Crambert G, Li C, Swee LK and Geering K: FXYD7, mapping of functional sites involved in endoplasmic reticulum export, association with and regulation of Na,K-ATPase. J Biol Chem. 279:30888–30895. 2004. View Article : Google Scholar : PubMed/NCBI | |
Geering K: Function of FXYD proteins, regulators of Na, K-ATPase. J Bioenerg Biomembr. 37:387–392. 2005. View Article : Google Scholar : PubMed/NCBI | |
Mayan H, Farfel Z and Karlish SJD: Renal Mg handling, FXYD2 and the central role of the Na,K-ATPase. Physiol Rep. 6:e138432018. View Article : Google Scholar : PubMed/NCBI | |
Lubarski I, Pihakaski-Maunsbach K, Karlish SJ, Maunsbach AB and Garty H: Interaction with the Na,K-ATPase and tissue distribution of FXYD5 (related to ion channel). J Biol Chem. 280:37717–37724. 2005. View Article : Google Scholar : PubMed/NCBI | |
Kadowaki K, Sugimoto K, Yamaguchi F, Song T, Watanabe Y, Singh K and Tokuda M: Phosphohippolin expression in the rat central nervous system. Brain Res Mol Brain Res. 125:105–112. 2004. View Article : Google Scholar : PubMed/NCBI | |
Béguin P, Cambert G, Monnet-Tschudi F, Uldry M, Horesberger JD, Garty H and Geering K: FXYD7 is a brain-specific regulator of Na,K-ATPase alpha1-beta isozymes. EMBO J. 21:3264–3273. 2002. View Article : Google Scholar | |
Yamaguchi F, Yamaguchi K, Tai Y, Sugimoto K and Tokuda M: Molecular cloning and characterization of a novel phospholemman-like protein from rat hippocampus. Brain Res Mol Brain Res. 86:189–192. 2001. View Article : Google Scholar : PubMed/NCBI | |
Zhu ZL, Zhao ZR, Zhang Y, Yang YH, Wang ZM, Cui DS, Wang MW, Kleeff J, Kayed H, Yan BY and Sun XF: Expression and significance of FXYD-3 protein in gastric adenocarcinoma. Dis Markers. 28:63–69. 2010. View Article : Google Scholar : PubMed/NCBI | |
Grzmil M, Voigt S, Thelen P, Hemmerlein B, Helmke K and Burfeind P: Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells. Int J Oncol. 24:97–105. 2004.PubMed/NCBI | |
Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S and Becchetti A: Targeting ion channels in cancer: A novel frontier in antineoplastic therapy. Curr Med Chem. 16:66–93. 2009. View Article : Google Scholar : PubMed/NCBI | |
Baker Bechmann M, Rotoli D, Morales M, Maeso Mdel C, García Mdel P, Ávila J, Mobasheri A and Martín-Vasallo P: Na,K-ATPase isozymes in colorectal cancer and liver metastases. Front Physiol. 7:92016. View Article : Google Scholar : PubMed/NCBI | |
Yang P, Cartwright C, Efuet E, Hamilton SR, Wistuba II, Menter D, Addington C, Shureiqi I and Newman RA: Cellular location and expression of Na+,K+-ATPase α subunits affect the anti-proliferative activity of oleandrin. Mol Carcinog. 53:253–263. 2014. View Article : Google Scholar : PubMed/NCBI | |
Garcia DG, de Castro-Faria-Neto HC, da Silva CI, de Souza e Souza KF, Gonçalves-de-Albuquerque CF, Silva AR, de Amorim LM, Freire AS, Santelli RE, Diniz LP, et al: Na/K-ATPase as a target for anticancer drugs: Studies with perillyl alcohol. Mol Cancer. 14:1052015. View Article : Google Scholar : PubMed/NCBI | |
Slingerland M, Cerella C, Guchelaar HJ, Diederich M and Gelderblom H: Cardiac glycosides in cancer therapy: From preclinical investigations towards clinical trials. Invest New Drugs. 31:1087–1094. 2013. View Article : Google Scholar : PubMed/NCBI | |
Prassas I, Karagiannis GS, Batruch I, Dimitromanolakis A, Datti A and Diamandis EP: Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks. Mol Cancer Ther. 10:2083–2093. 2011. View Article : Google Scholar : PubMed/NCBI | |
Liu N, Li Y, Su S, Wang N, Wang H and Li J: Inhibition of cell migration by ouabain in the A549 human lung cancer cell line. Oncol Lett. 6:475–479. 2013. View Article : Google Scholar : PubMed/NCBI | |
Bogdanov A, Moiseenko F and Dubina M: Abnormal expression of ATP1A1 and ATP1A2 in breast cancer. F1000Res. 6:102017. View Article : Google Scholar : PubMed/NCBI | |
Mony S, Lee SJ, Harper JF, Barwe SP and Langhans SA: Regulation of Na,K-ATPase β1-subunit in TGF-β2-mediated epithelial-to-mesenchymal transition in human retinal pigmented epithelial cells. Exp Eye Res. 115:113–122. 2013. View Article : Google Scholar : PubMed/NCBI | |
Li S, Dai Z, Yang D, Li W, Dai H, Sun B, Liu X, Xie X, Xu R and Zhao X: Targeting β2 subunit of Na+/K+-ATPase induces glioblastoma cell apoptosis through elevation of intracellular Ca2. Am J Cancer Res. 9:1293–1308. 2019.PubMed/NCBI | |
Rotoli D, Cejas MM, Maeso MC, Pérez-Rodríguez ND, Morales M, Ávila J, Mobasheri A and Martín-Vasallo P: The Na, K-ATPase β-Subunit isoforms expression in glioblastoma multiforme: Moonlighting roles. Int J Mol Sci. 18:23692017. View Article : Google Scholar : PubMed/NCBI | |
Sun MZ, Kim JM, Oh MC, Safaee M, Kaur G, Clark AJ, Bloch O, Ivan ME, Kaur R, Oh T, et al: Na+/K+-ATPase β2-subunit (AMOG) expression abrogates invasion of glioblastoma-derived brain tumor-initiating cells. Neuro Oncol. 15:1518–1531. 2013. View Article : Google Scholar : PubMed/NCBI | |
Hsu IL, Chou CY, Wu YY, Wu JE, Liang CH, Tsai YT, Ke JY, Chen YL, Hsu KF and Hong TM: Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma. Oncotarget. 7:62925–62938. 2016. View Article : Google Scholar : PubMed/NCBI | |
Li Y, Zhang X, Xu S, Ge J, Liu J, Li L, Fang G, Meng Y, Zhang H and Sun X: Expression and clinical significance of FXYD3 in endometrial cancer. Oncol Lett. 8:517–522. 2014. View Article : Google Scholar : PubMed/NCBI | |
Xue Y, Lai L, Lian W, Tu X, Zhou J, Dong P, Su D, Wang X, Cao X, Chen Y and Wang Q: SOX9/FXYD3/Src Axis is critical for ER + breast cancer stem cell function. Mol Cancer Res. 17:238–249. 2019. View Article : Google Scholar : PubMed/NCBI | |
Chen X, Sun M, Hu Y, Zhang H, Wang Z, Zhou N and Yan X: FXYD6 is a new biomarker of cholangiocarcinoma. Oncol Lett. 7:393–398. 2014. View Article : Google Scholar : PubMed/NCBI | |
Gao Q, Chen X, Duan H, Wang Z, Feng J, Yang D, Song L, Zhou N and Yan X: FXYD6: A novel therapeutic target toward hepatocellular carcinoma. Protein Cell. 5:532–543. 2014. View Article : Google Scholar : PubMed/NCBI | |
Raman P, Purwin T, Pestell R and Tozeren A: FXYD5 is a marker for poor prognosis and a potential driver for metastasis in ovarian carcinomas. Cancer Inform. 14:113–119. 2015. View Article : Google Scholar : PubMed/NCBI | |
Casemore D and Xing C: SERCA as a target for cancer therapies. Integr Cancer Sci Therap. 2:100–103. 2015. | |
Aubier M and Viires N: Calcium ATPase and respiratory muscle function. Eur Respir J. 11:758–766. 1998.PubMed/NCBI | |
Chemaly ER, Troncone L and Lebeche D: SERCA control of cell death and survival. Cell Calcium. 69:46–61. 2018. View Article : Google Scholar : PubMed/NCBI | |
Arbabian A, Brouland JP, Apáti Á, Pászty K, Hegedűs L, Enyedi Á, Chomienne C and Papp B: Modulation of endoplasmic reticulum calcium pump expression during lung cancer cell differentiation. FEBS J. 280:5408–5418. 2013. View Article : Google Scholar : PubMed/NCBI | |
Colomer-Saucedo JB, Loulousis MM, Copello VA, Krager SL, Tischkau SL and Copello JA: Pharmacological targeting of SERCA in breast cancer. FASEB J. 34 (Suppl):S12020. View Article : Google Scholar | |
Primeau JO, Armanious GP, Fisher ME and Young HS: The SarcoEndoplasmic reticulum calcium ATPase. Subcell Biochem. 87:229–258. 2018. View Article : Google Scholar : PubMed/NCBI | |
Sacchetto R, Bertipaglia I, Giannetti S, Cendron L, Mascarello F, Damiani E, Carafoli E and Zanotti G: Crystal structure of sarcoplasmic reticulum Ca2+-ATPase (SERCA) from bovine muscle. J Struct Biol. 178:38–44. 2012. View Article : Google Scholar : PubMed/NCBI | |
Stewart TA, Yapa KT and Monteith GR: Altered calcium signaling in cancer cells. Biochim Biophys Acta. 1848:2502–2511. 2015. View Article : Google Scholar : PubMed/NCBI | |
Celsi F, Pizzo P, Brini M, Leo S, Fotino C, Pinton P and Rizzuto R: Mitochondria, calcium and cell death: A deadly triad in neurodegeneration. Biochim Biophys Acta. 1787:335–344. 2009. View Article : Google Scholar : PubMed/NCBI | |
Yousef M, Vlachogiannis IA and Tsiani E: Effects of resveratrol against lung cancer: In vitro and in vivo studies. Nutrients. 9:12312017. View Article : Google Scholar : PubMed/NCBI | |
Papp B, Brouland JP, Arbabian A, Gélébart P, Kovács T, Bobe R, Enouf J, Varin-Blank N and Apáti A: Endoplasmic reticulum calcium pumps and cancer cell differentiation. Biomolecules. 2:165–186. 2012. View Article : Google Scholar : PubMed/NCBI | |
Sagara Y, Wade JB and Inesi G: A conformational mechanism for formation of a dead-end complex by the sarcoplasmic reticulum ATPase with thapsigargin. J Biol Chem. 267:1286–1292. 1992. View Article : Google Scholar : PubMed/NCBI | |
Jaskulska A, Janecka AE and Gach-Janczak K: Thapsigargin-from traditional medicine to anticancer drug. Int J Mol Sci. 22:42020. View Article : Google Scholar : PubMed/NCBI | |
Mahalingam D, Wilding G, Denmeade S, Sarantopoulas J, Cosgrove D, Cetnar J, Azad N, Bruce J, Kurman M, Allgood VE and Carducci M: Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: Results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours. Br J Cancer. 114:986–994. 2016. View Article : Google Scholar : PubMed/NCBI | |
Gu J, Liu H, Fu T and Xu Y: Thapsigargin increases apoptotic cell death in human hepatoma BEL-7404 cells. Cell Res. 5:59–65. 1995. View Article : Google Scholar | |
Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB and Isaacs JT: Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst. 95:990–1000. 2003. View Article : Google Scholar : PubMed/NCBI | |
Søhoel H, Jensen AM, Møller JV, Nissen P, Denmeade SR, Isaacs JT, Olsen CE and Christensen SB: Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. Bioorg Med Chem. 14:2810–2815. 2006. View Article : Google Scholar | |
Park KC, Kim SW, Jeon JY, Jo AR, Choi HJ, Kim J, Lee HG, Kim Y, Mills GB, Noh SH, et al: Survival of cancer stem-like cells under metabolic stress via CaMK2α-mediated upregulation of sarco/endoplasmic reticulum calcium ATPase expression. Clin Cancer Res. 24:1677–1690. 2018. View Article : Google Scholar : PubMed/NCBI | |
Riganti C, Doublier S, Viarisio D, Miraglia E, Pescarmona G, Ghigo D and Bosia A: Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression. Br J Pharmacol. 156:1054–1066. 2009. View Article : Google Scholar : PubMed/NCBI | |
De Ford C, Heidersdorf B, Haun F, Murillo R, Friedrich T, Borner C and Merfort I: The clerodane diterpene casearin J induces apoptosis of T-ALL cells through SERCA inhibition, oxidative stress, and interference with Notch1 signaling. Cell Death Dis. 7:e20702016. View Article : Google Scholar : PubMed/NCBI | |
Kim SL, Kim SH, Trang KT, Kim IH, Lee SO, Lee ST, Kim DG, Kang SB and Kim SW: Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer. Cancer Lett. 335:479–486. 2013. View Article : Google Scholar : PubMed/NCBI | |
Izquierdo-Torres E, Rodríguez G, Meneses-Morales I and Zarain-Herzberg A: ATP2A3 gene as an important player for resveratrol anticancer activity in breast cancer cells. Mol Carcinog. 56:1703–1711. 2017. View Article : Google Scholar : PubMed/NCBI | |
Vander Stricht DV, Raussens V, Oberg KA, Ruysschaert JM and Goormaghtigh E: Difference between the E1 and E2 conformations of gastric H+/K+-ATPase in a multilamellar lipid film system: Characterization by fluorescence and ATR-FTIR spectroscopy under a continuous buffer flow. Eur J Biochem. 268:2873–2880. 2001. View Article : Google Scholar : PubMed/NCBI | |
Streif D, Iglseder E, Hauser-Kronberger C, Fink KG, Jakab M and Ritter M: Expression of the non-gastric H+/K+ ATPase ATP12A in normal and pathological human prostate tissue. Cell Physiol Biochem. 28:1287–1294. 2011. View Article : Google Scholar : PubMed/NCBI | |
Abe K, Tani K, Nishizawa T and Fujiyoshi Y: Inter-subunit interaction of gastric H+,K+-ATPase prevents reverse reaction of the transport cycle. EMBO J. 28:1637–1643. 2009. View Article : Google Scholar : PubMed/NCBI | |
Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I and Munson K: The gastric H,K ATPase as a drug target: Past, present, and future. J Clin Gastroenterol. 41 (Suppl 2):S226–S242. 2007. View Article : Google Scholar : PubMed/NCBI | |
Ward RM and Kearns GL: Proton pump inhibitors in pediatrics: Mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs. 15:119–131. 2013. View Article : Google Scholar : PubMed/NCBI | |
Sakai H, Fujii T and Takeguchi N: Proton-potassium (H(+)/K(+)) ATPases: Properties and roles in health and diseases. Met Ions Life Sci. 16:459–483. 2016. View Article : Google Scholar : PubMed/NCBI | |
Dubey V, Han M, Kopec W, Solov'yov IA, Abe K and Khandelia H: K+ binding and proton redistribution in the E2P state of the H+, K+-ATPase. Sci Rep. 8:127322018. View Article : Google Scholar : PubMed/NCBI | |
Shin JM, Munson K, Vagin O and Sachs G: The gastric HK-ATPase: Structure, function, and inhibition. Pflugers Arch. 457:609–622. 2009. View Article : Google Scholar : PubMed/NCBI | |
McCormick CA, Samuels TL, Battle MA, Frolkis T, Blumin JH, Bock JM, Wells C, Yan K, Altman KW and Johnston N: H+/K+ATPase expression in the larynx of laryngopharyngeal reflux and laryngeal cancer patients. Laryngoscope. 131:130–135. 2021. View Article : Google Scholar : PubMed/NCBI | |
Judd LM, Andringa A, Rubio CA, Spicer Z, Shull GE and Miller ML: Gastric achlorhydria in H/K-ATPase-deficient (Atp4a(−/-)) mice causes severe hyperplasia, mucocystic metaplasia and upregulation of growth factors. J Gastroenterol Hepatol. 20:1266–1278. 2005. View Article : Google Scholar : PubMed/NCBI | |
Jakab M, Hofer S, Ravasio A, Huber F, Schmidt S, Hitzl W, Geibel JP, Fürst J and Ritter M: The putative role of the non-gastric H+/K+-ATPase ATP12A (ATP1AL1) as anti-apoptotic ion transporter: Effect of the H+/K+ ATPase inhibitor SCH28080 on butyrate-stimulated myelomonocytic HL-60 Cells. Cell Physiol Biochem. 34:1507–1526. 2014. View Article : Google Scholar : PubMed/NCBI | |
Yan D, Hu Y, Li S and Cheng M: A model of 3D-structure of H+, K+-ATPase catalytic subunit derived by homology modeling. Acta Pharmacol Sin. 25:474–479. 2004.PubMed/NCBI | |
Wang X, Liu C, Wang J, Fan Y, Wang Z and Wang Y: Proton pump inhibitors increase the chemosensitivity of patients with advanced colorectal cancer. Oncotarget. 8:58801–58808. 2017. View Article : Google Scholar : PubMed/NCBI | |
Ihraiz WG, Ahram M and Bardaweel SK: Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells. Acta Pharm. 70:179–190. 2020. View Article : Google Scholar : PubMed/NCBI | |
Hálfdánarson ÓÖ, Pottegård A, Lund SH, Ogmundsdottir MH, Ogmundsdottir HM and Zoega H: Use of proton pump inhibitors and mortality among Icelandic patients with prostate cancer. Basic Clin Pharmacol Toxicol. 126:484–491. 2020. View Article : Google Scholar | |
Tozzi M, Sørensen CE, Magni L, Christensen NM, Bouazzi R, Buch CM, Stefanini M, Duranti C, Arcangeli A and Novak I: Proton pump inhibitors reduce pancreatic adenocarcinoma progression by selectively targeting H+, K+-ATPases in pancreatic cancer and stellate cells. Cancers (Basel). 12:6402020. View Article : Google Scholar : PubMed/NCBI | |
Lin S, Lin B, Wang X, Pan Y, Xu Q, He JS, Gong W, Xing R, He Y, Guo L, et al: Silencing of ATP4B of ATPase H+/K+ transporting beta subunit by intragenic epigenetic alteration in human gastric cancer cells. Oncol Res. 25:317–329. 2017. View Article : Google Scholar : PubMed/NCBI | |
Zhang Q, Huang N, Wang J, Luo H, He H, Ding M, Deng WQ and Zou K: The H+/K+-ATPase inhibitory activities of trametenolic acid B from trametes lactinea (Berk.) Pat, and its effects on gastric cancer cells. Fitoterapia. 89:210–217. 2013. View Article : Google Scholar : PubMed/NCBI | |
Yeo M, Kim DK, Kim YB, Oh TY, Lee JE, Cho SW, Kim HC and Hahm KB: Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res. 10:8687–8696. 2004. View Article : Google Scholar : PubMed/NCBI | |
Lindner K, Borchardt C, Schöpp M, Bürgers A, Stock C, Hussey DJ, Haier J and Hummel R: Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer. J Exp Clin Cancer Res. 33:732014. View Article : Google Scholar : PubMed/NCBI | |
Ferrari S, Perut F, Fagioli F, Brach Del Prever A, Meazza C, Parafioriti A, Picci P, Gambarotti M, Avnet S, Baldini N and Fais S: Proton pump inhibitor chemosensitization in human osteosarcoma: From the bench to the patients' bed. J Transl Med. 11:2682013. View Article : Google Scholar : PubMed/NCBI | |
Goh W, Sleptsova-Freidrich I and Petrovic N: Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 17:439–446. 2014. View Article : Google Scholar : PubMed/NCBI | |
Lugini L, Sciamanna I, Federici C, Iessi E, Spugnini EP and Fais S: Antitumor effect of combination of the inhibitors of two new oncotargets: Proton pumps and reverse transcriptase. Oncotarget. 8:4147–4155. 2017. View Article : Google Scholar : PubMed/NCBI | |
Wu DC, Kuo CH, Tsay FW, Hsu WH, Chen A and Hsu PI: A pilot randomized controlled study of dexlansoprazole mr-based triple therapy for Helicobacter pylori infection. Medicine (Baltimore). 95:e26982016. View Article : Google Scholar : PubMed/NCBI | |
Otake K, Sakurai Y, Nishida H, Fukui H, Tagawa Y, Yamasaki H, Karashima M, Otsuka K and Inatomi N: Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate (TAK-438). Adv Ther. 33:1140–1157. 2016. View Article : Google Scholar : PubMed/NCBI | |
Inatomi N, Matsukawa J, Sakurai Y and Otake K: Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases. Pharmacol Ther. 168:12–22. 2016. View Article : Google Scholar : PubMed/NCBI | |
Singh N, Singh P, Shrivastva S, Mishra SK, Lakshmi V, Sharma R and Palit G: Gastroprotective effect of anti-cancer compound rohitukine: Possible role of gastrin antagonism and H(+) K (+)-ATPase inhibition. Naunyn-Schmiedebergs Arch Pharmacol. 385:277–286. 2012. View Article : Google Scholar : PubMed/NCBI | |
Mijatovic T, Dufrasne F and Kiss R: Cardiotonic steroids-mediated targeting of the Na(+)/K(+)-ATPase to combat chemoresistant cancers. Curr Med Chem. 19:627–646. 2012. View Article : Google Scholar : PubMed/NCBI | |
Bindu PH, Sastry GM, Murty US and Sastry GN: Structural and conformational changes concomitant with the E1-E2 transition in H(+)K(+)-ATPase: A comparative protein modeling study. Biochem Biophys Res Commun. 319:312–320. 2004. View Article : Google Scholar : PubMed/NCBI | |
Frankel AE, Eskiocak U, Gill JG, Yuan S, Ramesh V, Froehlich TW, Ahn C and Morrison SJ: Digoxin plus trametinib therapy achieves disease control in BRAF wild-type metastatic melanoma patients. Neoplasia. 19:255–260. 2017. View Article : Google Scholar : PubMed/NCBI | |
Koch KM, Smith DA, Botbyl J, Arya N, Briley LP, Cartee L, White JH, Beyer J, Dar MM, Chung HC, et al: Effect of lapatinib on oral digoxin absorption in patients. Clin Pharmacol Drug Dev. 4:449–453. 2015. View Article : Google Scholar : PubMed/NCBI | |
Lin J, Zhan T, Duffy D, Hoffman-Censits J, Kilpatrick D, Trabulsi EJ, Lallas CD, Chervoneva I, Limentani K, Kennedy B, et al: A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA. Am J Cancer Ther Pharmacol. 2:21–32. 2014.PubMed/NCBI | |
Jankowski JAZ, de Caestecker J, Love SB, Reilly G, Watson P, Sanders S, Ang Y, Morris D, Bhandari P, Brooks C, et al: Esomeprazole and aspirin in Barrett's oesophagus (AspECT): A randomised factorial trial. Lancet. 392:400–408. 2018. View Article : Google Scholar : PubMed/NCBI | |
Cheung KS and Leung WK: Long-term use of proton-pump inhibitors and risk of gastric cancer: A review of the current evidence. Therap Adv Gastroenterol. 12:1756284819834512019. View Article : Google Scholar : PubMed/NCBI | |
Hammadi M, Adi M, John R, Khoder GA and Karam SM: Dysregulation of gastric H,K-ATPase by cigarette smoke extract. World J Gastroenterol. 15:4016–4022. 2009. View Article : Google Scholar : PubMed/NCBI | |
Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA and Sørensen HT: Proton pump inhibitor use and risk of colorectal cancer: A population-based, case-control study. Gastroenterology. 133:755–760. 2007. View Article : Google Scholar : PubMed/NCBI | |
Roche VF: The chemically elegant proton pump inhibitors. Am J Pharm Educ. 70:1012006. View Article : Google Scholar : PubMed/NCBI | |
Inge LJ, Rajasekaran SA, Yoshimoto K, Mischel PS, McBride W, Landaw E and Rajasekaran AK: Evidence for a potential tumor suppressor role for the Na,K-ATPase beta1-subunit. Histol Histopathol. 23:459–467. 2008.PubMed/NCBI | |
Alevizopoulos K, Dimas K, Papadopoulou N, Schmidt EM, Tsapara A, Alkahtani S, Honisch S, Prousis KC, Alarifi S, Calogeropoulou T, et al: Functional characterization and anti-cancer action of the clinical phase II cardiac Na+/K+ ATPase inhibitor istaroxime: In vitro and in vivo properties and cross talk with the membrane androgen receptor. Oncotarget. 7:24415–22428. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chow DC and Forte JG: Functional significance of the beta-subunit for heterodimeric P-type ATPases. J Exp Biol. 198:1–17. 1995. View Article : Google Scholar : PubMed/NCBI | |
Peterson JA, Oblad RV, Mecham JC and Kenealey JD: Resveratrol inhibits plasma membrane Ca2+-ATPase inducing an increase in cytoplasmic calcium. Biochem Biophys Rep. 7:253–258. 2016.PubMed/NCBI | |
Madreiter-Sokolowski CT, Gottschalk B, Parichatikanond W, Eroglu E, Klec C, Waldeck-Weiermair M, Malli R and Graier WF: Resveratrol specifically kills cancer cells by a devastating increase in the Ca2+ coupling between the greatly tethered endoplasmic reticulum and mitochondria. Cell Physiol Biochem. 39:1404–1420. 2016. View Article : Google Scholar : PubMed/NCBI | |
Almasi S and El Hiani Y: Exploring the therapeutic potential of membrane transport proteins: Focus on cancer and chemoresistance. Cancers (Basel). 12:16242020. View Article : Google Scholar : PubMed/NCBI | |
McConkey DJ, Lin Y, Nutt LK, Ozel HZ and Newman RA: Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res. 60:3807–3812. 2000.PubMed/NCBI | |
Li H, Wang P, Gao Y, Zhu X, Liu L, Cohen L, Meng Z and Yang P: Na+/K+-ATPase α3 mediates sensitivity of hepatocellular carcinoma cells to bufalin. Oncol Rep. 25:825–830. 2011.PubMed/NCBI | |
Numazawa S, Shinoki MA, Ito H, Yoshida T and Kuroiwa Y: Involvement of Na+,K(+)-ATPase inhibition in K562 cell differentiation induced by bufalin. J Cell Physiol. 160:113–120. 1994. View Article : Google Scholar : PubMed/NCBI | |
Sun X, Ng TTH, Sham KWY, Zhang L, Chan MTV, Wu WKK and Cheng CHK: Bufalin, a traditional Chinese medicine compound, prevents tumor formation in two murine models of colorectal cancer. Cancer Prev Res (Phila). 12:653–666. 2019. View Article : Google Scholar : PubMed/NCBI | |
Yu CH, Kan SF, Pu HF, Jea Chien E and Wang PS: Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. Cancer Sci. 99:2467–2476. 2008. View Article : Google Scholar : PubMed/NCBI | |
Kang MA, Kim MS, Kim W, Um JH, Shin YJ, Song JY and Jeong JH: Lanatoside C suppressed colorectal cancer cell growth by inducing mitochondrial dysfunction and increased radiation sensitivity by impairing DNA damage repair. Oncotarget. 7:6074–6087. 2016. View Article : Google Scholar : PubMed/NCBI | |
Huang YT, Chueh SC, Teng CM and Guh JH: Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 cells. Biochem Pharmacol. 67:727–733. 2004. View Article : Google Scholar : PubMed/NCBI | |
Ono Y, Chiba S, Yano H, Nakayama N, Saio M, Tsuruma K, Shimazawa M, Iwama T and Hara H: Glycoprotein nonmetastatic melanoma protein B (GPNMB) promotes the progression of brain glioblastoma via Na+/K+-ATPase. Biochem Biophys Res Commun. 481:7–12. 2016. View Article : Google Scholar : PubMed/NCBI | |
Rocha SC, Pessoa MT, Neves LD, Alves SL, Silva LM, Santos HL, Oliveira SM, Taranto AG, Comar M, Gomes IV, et al: 21-Benzylidene digoxin: A proapoptotic cardenolide of cancer cells that up-regulates Na,K-ATPase and epithelial tight junctions. PLoS One. 9:e1087762014. View Article : Google Scholar : PubMed/NCBI | |
Denmeade SR and Isaacs JT: The SERCA pump as a therapeutic target: Making a ‘smart bomb’ for prostate cancer. Cancer Biol Ther. 4:21–29. 2005. View Article : Google Scholar : PubMed/NCBI | |
Fan L, Li A, Li W, Cai P, Yang B, Zhang M, Gu Y, Shu Y, Sun Y, Shen Y, et al: Novel role of Sarco/endoplasmic reticulum calcium ATPase 2 in development of colorectal cancer and its regulation by F36, a curcumin analog. Biomed Pharmacother. 68:1141–1148. 2014. View Article : Google Scholar : PubMed/NCBI | |
Jia J, Qin Y, Zhang L, Guo C, Wang Y, Yue X and Qian J: Artemisinin inhibits gallbladder cancer cell lines through triggering cell cycle arrest and apoptosis. Mol Med Rep. 13:4461–4468. 2016. View Article : Google Scholar : PubMed/NCBI |